At Novatrials, we can state with confidence that we offer our clients efficiency, savings in resources and superior data quality, ensuring that your therapy, drug or medical device in any of these therapeutic areas stands up to local and global requirements.
Before we embark on the trial itself, we shall determine its viability to avoid spiraling costs and expanding timelines. Using our extensive experience, we shall help you identify risks to your study and put in place strategies to mitigate them.
Our team has vast clinical experience in conducting research of pharmaceutical products for the following medical indications:
Renal Cell Carcinoma
DMD - Duchenne muscular dystrophy
GHD – Growth Hormone Deficiency
Type 2 Diabetes Mellitus
SIRT – Selective Internal Radiation Therapy
CTO – Chronic Total Occlusions
Corneal Edema - Lens
Corneal Edema – Implant
BPH-Benign Prostate Hypertrophy
IUB-Intra Uterine Ball
Genetic and Pharmacogenetics studies
Despite the regulatory challenges that have traditionally held up the approval in Israel of studies in which genetic information has been collected, we have successfully obtained long-term approvals for sub-research in all indications, with particularly attractive schedules.
Mesenchymal stem cells
Anti-angiogenic agents based on an adenovirus vector